CAY10603, an inhibitor of HDAC6, acted synergistically with gefitinib to induce the apoptosis of lung adenocarcinoma cell lines by destabilizing EGFR [70] (Figure 4A), whereas sorafenib activated EGFR signaling by stabilizing HDAC6 [71] (Figure 4A). This evidence concerns the gene EGFR and lung adenocarcinoma.